Trade-Ideas LLC identified

Masimo

(

MASI

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Masimo as such a stock due to the following factors:

  • MASI has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.2 million.
  • MASI has traded 6,054 shares today.
  • MASI is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MASI with the Ticky from Trade-Ideas. See the FREE profile for MASI NOW at Trade-Ideas

More details on MASI:

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. MASI has a PE ratio of 29. Currently there are 4 analysts that rate Masimo a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Masimo has been 355,500 shares per day over the past 30 days. Masimo has a market cap of $2.4 billion and is part of the health care sector and health services industry. The stock has a beta of 0.63 and a short float of 4.3% with 4.16 days to cover. Shares are up 15.7% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Masimo as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow.

Highlights from the ratings report include:

  • Powered by its strong earnings growth of 39.47% and other important driving factors, this stock has surged by 33.68% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, MASI should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • MASIMO CORP has improved earnings per share by 39.5% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, MASIMO CORP increased its bottom line by earning $1.56 versus $1.30 in the prior year. This year, the market expects an improvement in earnings ($1.83 versus $1.56).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 34.4% when compared to the same quarter one year prior, rising from $20.52 million to $27.58 million.
  • MASI's revenue growth trails the industry average of 31.0%. Since the same quarter one year prior, revenues rose by 10.8%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, MASIMO CORP's return on equity significantly exceeds that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.